Lin Patrick 4

What Happened Lin Patrick, Processa Pharmaceuticals' Chief Business & Strategy Officer, reported a purchase of 1,603 shares on 2026-03-31 at $2.54 per share, for a total cash outlay of approximately $4,064. The Form 4 shows a purchase (transaction code P), which is a direct acquisition rather than a sale or option exercise — purchases can be viewed as a more informative (potentially bullish) signal than routine sell transactions, though motivations are not disclosed.

Key Details

• Transaction date: 2026-03-31; Price: $2.54 per share; Shares acquired: 1,603; Total value: ~$4,064.
• Transaction type: P = Purchase (open-market or private purchase as indicated on the form).
• Filing date: 2026-04-01 — filed the business day after the trade (timely).
• Shares owned after transaction: not specified in the provided filing details.
• No footnotes provided in the supplied data (e.g., no 10b5-1 plan, tax withholding, or gift notation).

Context This was a straightforward equity purchase by an executive and not a derivative transaction or option exercise. The filing appears timely, so there’s no late-reporting concern in the provided record. As always, purchases by insiders are factual data points; they do not prove intent or predict future stock performance and should be considered alongside company fundamentals and news.